Aardvark Therapeutics, Inc. - Common Stock (NQ:AARD)

Attention Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Coastal Financial Corporation (NASDAQ: CCB); Erasca, Inc. (NASDAQ: ERAS); and Power Solutions International, Inc. (NASDAQ: PSIX): Grabar Law Office is Investigating Claims on

October 15, 2026

Important Notice to Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Coastal Financial Corporation (NASDAQ: CCB); New Era Energy & Digital, Inc. (NASDAQ: NUAI); and The Simply Good Foods Company (NASDAQ: SMPL): Grabar Law Office is

Performance

52-Week Range 77.5% below 52-week high

3.740

3.3552W Low 16.6052W High

1 Week 23.3% below 1-week high

3.641W Low 4.881W High

Aardvark Therapeutics, Inc. - Common Stock (AARD) traded between $3.35 and $16.60 over the past 52 weeks and last traded at $3.74, 77.5% below its 52-week high. Over the past week it ranged between $3.64 and $4.88.

Past 12 Months

-16.0%

-30.5%

-32.4%

-33.8%

-71.6%

-69.5%

1W -$0.71

1M -$1.64

3M -$1.79

6M -$1.91

YTD -$9.45

1Y -$8.54

AARD was -69.5% over the past year, -33.8% over six months, -71.6% year to date, -16.0% in the last week.

12 Months vs Market

AARD

-69.5%

DIA

+11.1%

SPY

+14.2%

QQQ

+17.5%

IWM

+9.3%

Over the past 12 months AARD returned -69.5% versus DIA (Dow) +11.1%, SPY (S&P 500) +14.2%, QQQ (Nasdaq 100) +17.5% and IWM (Russell 2000) +9.3%.

Volume & Liquidity 1.03× 3-mo avg

Today 135,284 3-mo avg 131.6K

124.3K

118.9K

131.6K

198.9K

YTD

225.7K

221.9K

AARD most recently traded 135,284 shares against a 3-month average daily volume of 131.6K.

More News

October 14, 2026

Pomerantz Law Firm Announces the Filing of a Class Action Against Aardvark Therapeutics, Inc. and Certain Officers and Directors – AARD

October 13, 2026

From Pomerantz LLP

SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of October 13, 2026 in Aardvark Therapeutics, Inc. Lawsuit - AARD

October 13, 2026

From SueWallSt

CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Aardvark (AARD) Investors of Securities Class Action Lawsuit Deadline on October 13, 2026

October 13, 2026

From Faruqi & Faruqi, LLP

Via Business Wire

Levi & Korsinsky Reminds Aardvark Therapeutics Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 13, 2026 - AARD

October 12, 2026

From Levi & Korsinsky, LLP

AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law

October 12, 2026

Attention Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Coastal Financial Corporation (NASDAQ: CCB); Duolingo, Inc. (NASDAQ: DUOL); and Ensign Group, Inc. (NASDAQ: ENSG): Grabar Law Office is Investigating Claims on Your Behalf

October 10, 2026

URGENT AARDVARK DEADLINE: Bragar Eagel & Squire, P.C. Urges Aardvark Therapeutics, Inc. Investors to Contact the Firm Seeking Lead Plaintiff Role Before October 13th

October 10, 2026

From Bragar Eagel & Squire

AARD UPCOMING DEADLINE: Levi & Korsinsky Alerts Aardvark Therapeutics, Inc. Stockholders of Securities Class Action - Contact the Firm

October 09, 2026

From Levi & Korsinsky, LLP

Via ACCESS Newswire

AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law

October 08, 2026

Attention Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Coastal Financial Corporation (NASDAQ: CCB); Erasca, Inc. (NASDAQ: ERAS); and New Era Energy & Digital, Inc. (NASDAQ: NUAI): Grabar Law Office is Investigating Claims on Your

October 08, 2026

Aardvark Therapeutics Appoints Clinical Development Leader David Zhang, Ph.D., MBA, to its Board of Directors

October 08, 2026

From Aardvark Therapeutics, Inc.

AARD Deadline: Rosen Law Firm Urges Aardvark Therapeutics, Inc. (NASDAQ: AARD) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights

October 07, 2026

From The Rosen Law Firm, P.A.

Via Business Wire

Pomerantz Law Firm Announces the Filing of a Class Action Against Aardvark Therapeutics, Inc. and Certain Officers and Directors – AARD

October 06, 2026

From Pomerantz LLP

Important Notice to Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); and GPGI, Inc., f/k/a CompoSecure, Inc. (NYSE: GPGI); PROCEPT BioRobotics Corporation (NASDAQ: PRCT); and The Simply Good Foods Company (NASDAQ: SMPL): Grabar Law

October 06, 2026

Bragar Eagel & Squire, P.C. Urges Aardvark Therapeutics, Inc. Investors to Contact the Firm Seeking Lead Plaintiff Role Before October 13th

October 05, 2026

From Bragar Eagel & Squire

If You Lost Money Investing in Aardvark Therapeutics, Inc. (AARD) Contact Robbins LLP for Information About Recovering Your Losses

October 05, 2026

Via Newsfile

AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law

October 05, 2026

Important Notice to Long-Term Shareholders of Anavex Life Sciences Corp. (NASDAQ: AVXL); Ardelyx, Inc. (NASDAQ: ARDX); Aardvark Therapeutics, Inc. (NASDAQ: AARD); and GPGI, Inc., f/k/a CompoSecure, Inc. (NYSE: GPGI): Grabar Law Office is Investigating

October 05, 2026

Aardvark Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

October 02, 2026

From Aardvark Therapeutics, Inc.

AARDVARK DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Aardvark Therapeutics, Inc. Investors to Secure Counsel Before Important October 13 Deadline in Securities Class Action – AARD

October 02, 2026

From The Rosen Law Firm PA

AARD Shareholder Alert: Aardvark Therapeutics, Inc. Securities Class Action Lawsuit - Investors Should Contact Levi & Korsinsky

October 02, 2026

From Levi & Korsinsky, LLP

Via ACCESS Newswire

AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law

October 01, 2026